Samsung Pharmaceutical KRX:001360KOSPI
삼성제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked19since Sep 11
In Q2 2026, Samsung Pharmaceutical reported revenue of ₩9.9bn, down 9.1% year on year, and an operating loss of ₩5.0bn. Samsung Pharmaceutical (삼성제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Clinical trial filing 4 quarters of losses Screener
Samsung Pharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩9.9bn | -9.1% | −₩5.0bn margin −50.4% | −₩56.6bn |
| Q1 2026 | ₩9.0bn | -20.6% | −₩1.9bn margin −21.0% | ₩8.8bn |
| Q4 2025 derived | ₩11.8bn | +12.9% | −₩5.4bn margin −45.8% | −₩59.1bn |
| Q3 2025 | ₩12.0bn | +8.3% | −₩3.9bn margin −32.1% | −₩30.2bn |
| Q2 2025 | ₩10.9bn | +3.0% | −₩4.3bn margin −39.5% | ₩63.6bn |
| Q1 2025 | ₩11.4bn | -6.7% | −₩4.5bn margin −39.6% | ₩37.2bn |
| Q4 2024 derived | ₩10.5bn | -12.9% | −₩2.9bn margin −27.6% | −₩17.3bn |
| Q3 2024 | ₩11.1bn | -5.4% | −₩3.6bn margin −32.6% | ₩18.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Samsung Pharmaceutical top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Samsung Pharmaceutical news Korean headlines
-
Major삼성제약, 진행성핵상마비 국내 2b/3상 임상시험계획서 제출
1 more on this story · 1 outlets
- 삼성제약, ‘GV1001’ 진행성핵상마비 국내 2b/3상 IND 제출…“적응적 설계 도입”이투데이 · Sep 28 17:31